

BRIAN SANDOVAL
Governor



RICHARD WHITLEY, MS
Director

MARTA JENSEN
Administrator

DEPARTMENT OF HEALTH AND HUMAN SERVICES
DIVISION OF HEALTH CARE FINANCING AND POLICY
1100 East William Street, Suite 101
Carson City, Nevada 89701
Telephone (775) 684-3676 • Fax (775) 687-3893
<http://dhcfp.nv.gov>

November 6, 2017

Inter-Tribal Council of Nevada
Executive Board President
Vinton Hawley, Chairman
Pyramid Lake Paiute Tribe
P.O. Box 256
Nixon, NV 89424

Dear Tribal Members:

In accordance with established consultation guidelines, the Division of Health Care Financing and Policy (DHCFP) is notifying Nevada tribes of the following proposed change in policy:

Revisions to Medicaid Services Manual, Chapter 1200, Appendix A, were made to reflect approved actions by the Drug Use Review (DUR) Board at the October 19, 2017 meeting. The DUR board approved the new prior authorization criteria for Austedo® (deutetrabenazine), Brineura® (cerliponase alfa), Ingrezza® (Valbenazine), Xadago (safinamide) and Emflaza® (deflazacort). The DUR Board also approved new prior authorization criteria for Codeine and Ultram® (Tramadol) for pediatric patients. The DUR Board revised prior authorization criteria for Xolair® (omalizumab) for pediatric patients.

There is no anticipated fiscal impact to the Tribal Governments.

If you would like a consultation regarding this new policy, please contact Colleen McLachlan at (775) 684-3722 who will schedule a meeting. We would appreciate a reply within 30 days from the date of this letter. If we do not hear from you within this time, we will consider this an indication that no consultation is requested.

Sincerely,

Lynne Foster
Chief of Division Compliance

Cc: Shannon Sprout, Deputy Administrator, DHCFP
Duane Young, Chief, Policy Development & Program Management, DHCFP
Holly Long, SSPS II, Policy Development & Program Management, DHCFP
Jodi Patton, SSPS III, Policy Development & Program Management, DHCFP